Pharmanutra

Investor Presentation • Feb 22, 2024

PHARMANUTRA

DISCLAIMER

2

This document has been prepared by Pharmanutra S.p.A. (the "Company") for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may not be reproduced or distributed, in whole or in part, by any person other than the Company.

This document may contain forward-looking statements about the Company based on current expectations and opinions developed by the Company, as well as based on current plans, estimates, projections and projects of the Company. These forward-looking statements are subject to significant risks and uncertainties (many of which are outside the control of Pharmanutra) which could cause a material difference between forward-looking information and actual future results. The Company does not make any guarantee that subsequent to the date of the document, there will not be any changes to the activities and/or earnings situation of the Company.

Any reference to past performance or trends or activities of the Company shall not be taken as a representation or indication that such performance, trends or activities will continue in the future.

This document does not constitute a proposal to execute a contract, an offer or invitation to purchase, subscribe or sell for any financial instrument and neither it or any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. Any decision to purchase, subscribe or sell for securities will have to be made independently of this presentation. Therefore, nothing in this presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.

Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.

All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a comprehensive representation of the Company's cash generation performance.

All forward–looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document and are expressly qualified in their entirety by the cautionary statements included elsewhere in this document. The financial projections are preliminary and subject to change; the Company undertakes no obligation to update or revise these forward–looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks, and the assumptions underlying the projections may be inaccurate in any material respect. Therefore, the actual results achieved may vary significantly from the forecasts, and the variations may be material.

By receiving this Presentation, you acknowledge and agree to be bound by the foregoing terms, conditions, limitations and restrictions.

GROUP

THE GROUP

PHARMANUTRA GROUP

4

PharmaNutra holds 100% of Junia Pharma, Alesco and Akern.

Just three years after the listing on the AIM market of the Italian Stock Exchange, in December 2020 the Group switched to trading in the EURONEXT STAR MILAN.

2023	Distribution of Cetilar® and Cetilar® Nutrition lines
	Distribution of Cetilar® and other main goup products
2022
	Research and development of bioimpedance medical devices and software for body composition analysis
2010
	Medical products and devices, OTC and dietary supplements for children
2003
	Medical devices and dietary supplements for adults
2000
	Development and manufacturing of unique and innovative

THE NEW HEADQUARTER

MANAGE EVERY ACTIVITIES DIRECTLY : FROM INGREDIENT DISCOVERY TO END PRODUCT SALE

R&D

5

• INGREDIENT DISCOVERY
• PHARMACEUTICAL FORM DEVELOPMENT
• PRE-CLINICAL STUDIES
• PATENT PROTECTION

PRODUCTION SITE

• QC LABORATORY
• PRODUCTION CYCLE
• PRODUCT BATCH RELEASE
• PRODUCT TEST & TUNING

FUNCTIONS

• COMMERCIAL BACK OFFICE
• PRODUCTION PLANNING
• MARKETING & COMMUNICATION
• FINANCE, ADMINISTRATION, IT AND HR

THE NEW HQ: THE MAKING OF

6

THE GROUP

PHARMANUTRA'S UNIQUENESS Intellectual property protection

8

No player in the dietary supplements and medical devices industry has these 4 STRONG PILLARS IN ONE SINGLE COMPANY

SPEED UP R&D & INNOVATION

9

02 01 03 INNOVATION

• Sucrosomial® vitamines development
• Discovery of novel bone metabolism frontiers
• Newer evidences in new applications on our sucrosomial® iron

NEW LABORATORY

The new HQ will hold one of the most innovative nutritional research & development laboratory in Europe

R&D

• Exclusive lab models for the simulation of digestion and uptake of nutrients
• Increased prototipes in vitro scanning capabilities
• Higher efficacy second generation sucrosomes

RESEARCH MODELS

• Human cell systems
• Animal models: Ex-vivo In-vivo
• Healthy people
• Patients

10

FIELDS OF RESEARCH

• ULTRA: Minerals Vitamines Extracts and others • CFA, Cetylated fatty acids

Organoids Cells culture Sucrosomial® Prototipes

+ new formulations

R&D CLINICAL RESEARCH ACTIVITIES

R&D CLINICAL RESEARCH FIGURES

PRODUCT PORTFOLIO

14

CETILAR® NUTRITION

COMMUNICATION INVESTMENTS

Investments in tailored marketing & communication campaign, exploiting Cetilar strong franchise in sport

INNOVATIVE PRODUCTS PORTFOLIO

Premium products with proprietary formulation thanks to the uniqueness of the raw materials

PARTNER OF LUNA ROSSA PRADA PIRELLI

Human Performance Partner of the Luna Rossa Prada Pirelli challenge for the 37° America's Cup

B2B

Specific sales network created to promote products to doctors, pharmacies, sport shops and professional sport teams

E - COMMERCE

Development and management of a proprietary B2C e-commerce web site

THE MOST RECENT R&D OUTCOME...

Results suggest that orodispersible Sucrosomial® Vitamin D3 dissolves and absorbs quickly and effectively in the body, compared to conventional vitamin D3 formulations,

demonstrating a high safety and tolerability ...AND MORE TO COME

SPORT - A BUSINESS OPPORTUNITY

A UNIQUE PROPOSAL FOR ATHLETES' PERFORMANCE

nutrition to support athletes' performance

18

SPORT MARKETING

19

Pre-match & medical partner

PHARMANUTRA PARTNERS WITH THE LUNA ROSSA PRADA PIRELLI TEAM FOR THE 37th EDITION OF THE AMERICA'S CUP

Physical condition, injury prevention, nutrition and mental preparation

20

KEY ECONOMIC FIGURES

NET REVENUES GROWTH

PROFITABILITY EVOLUTION

23

INTERNATIONAL BUSINESS MODEL

24

Our Partners are exclusive distributors in their territories.

Scientific knowledge and research activities are shared through meetings with the partner sales force and through an e-learning portal.

Partners are constantly supported from order to shipment by our Operation Department.

Medical detailing and marketing experience are shared with partners in order to support them to develop the continuously growing business.

PharmaNutra operates in 85 countries with 50 partners, carefully selected among the best international pharmaceutical and nutraceutical companies.

THE FUTURE

GROWTH BOOSTERS

THE NEW GROWTH DRIVERS FOR THE NEXT 5 TO 10 YEARS

THE RIGHT MOMENTUM TO INVEST IN LONG TERM BUSINESS OPPORTUNITIES

26

Financial strenght

Solid double-digit organic growth trend in terms of sales and profitability

Significant potential market opportunies to exploit

Capabilty to support existing and future investments with sustainable financial risk

ESG ROADMAP

Pharmanutra Group has defined a clear roadmap to drive Sustainability with objectives of creating long term value for its stakeholders